MIRA Pharmaceuticals logo

MIRA PharmaceuticalsNASDAQ: MIRA

Profile

Sector:

Healthcare

Country:

United States

IPO:

14 August 2023

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$26.90 M
-72%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-85%vs. 3y high
94%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:56:30 GMT
$1.82-$0.42(-18.75%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

MIRA Latest News

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
accesswire.com27 September 2024 Sentiment: POSITIVE

Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic pain MIAMI, FL / ACCESSWIRE / September 27, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company developing innovative therapies for neurologic and neuropsychiatric disorders, today announced that new preclinical data on its lead development product, Ketamir-2, will be presented at the 18th Annual Pain Therapeutics Summit, taking place on October 28-29, 2024, in Boston, MA (the "Summit"). The presentation, entitled "Selective NMDA Receptor Modulation: The Superior Efficacy of Ketamir-2 in Neuropathic Pain Treatment," will showcase the breakthrough finding that Ketamir-2 achieved a complete reversal of neuropathic pain in preclinical models.

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
accesswire.com18 September 2024 Sentiment: POSITIVE

MIAMI, FL / ACCESSWIRE / September 18, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neuropsychiatric disorders, today announced significant progress in the clinical development planning for its novel oral ketamine analog. As part of its strategic development plan, MIRA is prioritizing the early demonstration of clinical efficacy, potentially as early as 2025, through innovative Phase I/II study designs.

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
accesswire.com11 September 2024 Sentiment: POSITIVE

MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neuropsychiatric disorders, announced today that it has selected neuropathic pain as the initial and primary indication for its novel oral ketamine analog, Ketamir-2. The company has submitted a request for a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in November 2024.

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
accesswire.com26 August 2024 Sentiment: POSITIVE

Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain Thresholds MIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is proud to announce a major breakthrough in the treatment of neuropathic pain. A recent pre-clinical study in rats demonstrated that its novel oral ketamine analog, Ketamir-2, produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose.

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
accesswire.com19 August 2024 Sentiment: POSITIVE

MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, is pleased to provide a comprehensive update on its recent achievements and scientific advancements as it nears a crucial milestone: the submission of its Investigational New Drug (IND) application by the end of the year. This update highlights the company's strategic progress, significant scientific breakthroughs, and the expertise driving its innovative drug candidates toward clinical trials.

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action
accesswire.com25 July 2024 Sentiment: POSITIVE

Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new insights garnered from additional, recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2. Ketamir-2 is MIRA's drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders.

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?
investorplace.com23 July 2024 Sentiment: NEUTRAL

Mira Pharmaceuticals (NASDAQ: MIRA ) stock is down on Tuesday as the clinical-stage pharmaceutical company's shares come off of a major rally on Monday. Shares of MIRA stock closed out Monday's normal trading hours up 627.4%.

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
accesswire.com22 July 2024 Sentiment: POSITIVE

New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 22, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. The additional data announced today continues a string of promising preclinical results announced by MIRA in recent months for Ketamir-2 as MIRA works towards its goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of this year which, if granted, would allow for human testing of Ketamir-2.

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
prnewswire.com24 June 2024 Sentiment: POSITIVE

New preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the potential for safer mental health treatments MIAMI , June 24, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog. The new data highlights Ketamir's potential to provide therapeutic benefits without inducing schizophrenia-like behavior or hyper-locomotor activity.

MIRA Announces Positive Test Results
benzinga.com17 June 2024 Sentiment: POSITIVE

The company announced that it achieved positive preclinical study results for Ketamir-2, its Novel Oral ketamine Analog.

What type of business is MIRA Pharmaceuticals?

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

What sector is MIRA Pharmaceuticals in?

MIRA Pharmaceuticals is in the Healthcare sector

What industry is MIRA Pharmaceuticals in?

MIRA Pharmaceuticals is in the Drug Manufacturers - General industry

What country is MIRA Pharmaceuticals from?

MIRA Pharmaceuticals is headquartered in United States

When did MIRA Pharmaceuticals go public?

MIRA Pharmaceuticals initial public offering (IPO) was on 14 August 2023

What is MIRA Pharmaceuticals website?

https://mirapharmaceuticals.com

Is MIRA Pharmaceuticals in the S&P 500?

No, MIRA Pharmaceuticals is not included in the S&P 500 index

Is MIRA Pharmaceuticals in the NASDAQ 100?

No, MIRA Pharmaceuticals is not included in the NASDAQ 100 index

Is MIRA Pharmaceuticals in the Dow Jones?

No, MIRA Pharmaceuticals is not included in the Dow Jones index

When was MIRA Pharmaceuticals the previous earnings report?

No data

When does MIRA Pharmaceuticals earnings report?

The next expected earnings date for MIRA Pharmaceuticals is 13 November 2024